Bentley Pharmaceuticals, Inc. has secured capacity at Cardinal Health’s North Raleigh, NC facility for the scale-up and manufacture of clinical supplies of its intranasal insulin product candidate, facilitating the expansion of clinical trials. The product candidate utilizes Bentley’s CPE-215 drug delivery technology to deliver insulin directly through diabetic patients’ nasal mucosa using a small, discreet nasal spray. Cardinal Health will manufacture clinical supplies of...